0001237899-20-000001.txt : 20200106 0001237899-20-000001.hdr.sgml : 20200106 20200106160244 ACCESSION NUMBER: 0001237899-20-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200106 DATE AS OF CHANGE: 20200106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SING GEORGE L CENTRAL INDEX KEY: 0001225471 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 20509611 MAIL ADDRESS: STREET 1: LANCET CAPITAL STREET 2: 45 ROCKEFELLER PLAZA STE 2008 CITY: NEW YORK STATE: NY ZIP: 10111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2020-01-02 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001225471 SING GEORGE L 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 0 0 0 Common Stock 2020-01-02 4 M 0 15000 24.41 A 130095 D Common Stock 2020-01-02 4 S 0 15000 371.98 D 115095 D Common Stock 2020-01-02 4 A 0 320 0.0 A 115415 D Common Stock 3000 I by Spouse Common Stock 4500 I by Spouse/Cust Son Common Stock 10000 I by Trust for Son Non-Qualified Stock Option (right to buy) 24.41 2020-01-02 4 M 0 15000 0.0 D 2020-01-04 Common Stock 15000 0 D Non-Qualified Stock Option (right to buy) 374.12 2020-01-02 4 A 0 4361 0.0 A 2030-01-02 Common Stock 4361 4361 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 15,000 shares of the Issuer's common stock on January 2, 2020 at prices ranging from $371.98 to $371.99. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2020. Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. By: Beverly Dubs as attorney-in-fact For: George L. Sing 2020-01-06